Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
07 January 2002Website:
http://www.ipatherapeutics.comNext earnings report:
13 December 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 24 min agoDividend
Analysts recommendations
Institutional Ownership
IPA Latest News
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPA's latest advancements in AI-driven design, biologics innovation, and strategic technological developments. Highlights of TECHDAY: Prese.
LOS ANGELES--(BUSINESS WIRE)-- #apartmentbrokers--Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts District.
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q1 2025 Earnings Conference Call September 16, 2024 10:30 AM ET Company Participants Jennifer Bath - CEO Kristin Taylor - CFO Conference Call Participants Swayampakula Ramakanth - H.C.
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09.
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2025, on Monday, September 16, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecis.
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.10.
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) today announces the rescheduling of its full year fiscal 2024 financial results and business highlights release. Originally set for July 25, 2024, the new release date is Monday, July 29, 2024, and will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary valuation calculations on goodwi.
ATLANTA, July 19, 2024 (GLOBE NEWSWIRE) -- Calling all 17s1! SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), one of the largest craft brewers in the Southeast and a subsidiary of Tilray Brands, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY and TSX: TLRY), is teaming up with Atlanta United to release Rowdy Peach IPA, a lively and vibrant new brew that celebrates the 5-Stripes and its passionate legion of supporters.
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand, is collaborating with PGxAI to leverage BioStrand's patented Foundation AI Model, LENSai. This collaboration advances the precision medicine field of pharmacogenomics and supports LENSai Application Programming Interface (“API”) commercial rollout through expanding LENSai fe.
ImmunoPrecise Antibodies Ltd. (IPA) Q3 2024 Earnings Call Transcript
What type of business is ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes. Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services. The company is headquartered in Victoria, Canada.
What sector is ImmunoPrecise Antibodies in?
ImmunoPrecise Antibodies is in the Healthcare sector
What industry is ImmunoPrecise Antibodies in?
ImmunoPrecise Antibodies is in the Biotechnology industry
What country is ImmunoPrecise Antibodies from?
ImmunoPrecise Antibodies is headquartered in Canada
When did ImmunoPrecise Antibodies go public?
ImmunoPrecise Antibodies initial public offering (IPO) was on 07 January 2002
What is ImmunoPrecise Antibodies website?
https://www.ipatherapeutics.com
Is ImmunoPrecise Antibodies in the S&P 500?
No, ImmunoPrecise Antibodies is not included in the S&P 500 index
Is ImmunoPrecise Antibodies in the NASDAQ 100?
No, ImmunoPrecise Antibodies is not included in the NASDAQ 100 index
Is ImmunoPrecise Antibodies in the Dow Jones?
No, ImmunoPrecise Antibodies is not included in the Dow Jones index
When was ImmunoPrecise Antibodies the previous earnings report?
No data
When does ImmunoPrecise Antibodies earnings report?
The next expected earnings date for ImmunoPrecise Antibodies is 13 December 2024